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Extranodal lymphomas of the gastrointestinal tract
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Abstract
Extranodal lymphomas commonly involve the gastrointestinal tract (GI) and often present
a diagnostic challenge for both clinicians and pathologists. Extranodal GI lymphomas (EGIL)
have varied aetiology and may present as an acute emergency or chronically with vague
abdominal symptoms in every age group. Morphologically they are as varied as any nodal
lymphoma. The optimal diagnosis subclassification of these lesions requires a high index of
suspicion on the part of the clinician, skilled endoscopist, or surgeon and a pathologist familiar
with a range of presentations and diagnostic criteria. This review paper focuses on EGIL from
the pathologist’s perspective.
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Streszczenie
Pozawęzłowe chłoniaki często zajmują przewód pokarmowy (GI) i są wtedy dużym wyzwaniem
diagnostycznym dla klinicystów i patologów. Pozawęzłowe chłoniaki przewodu pokarmowego
(EGIL) cechują różna etiologia i prezentacje kliniczne, obejmujące ostre lub przewlekłe objawy
brzuszne. Mogą wystąpić w każdym przedziale wieku i mieć zróżnicowany obraz morfologicz-
ny, podobnie jak w przypadku chłoniaków o lokalizacji węzłowej. Prawidłowego rozpoznania
EGIL powinno się dokonywać na podstawie danych klinicznych, wyników badań uzyskanych
metodami endoskopowymi i chirurgicznymi oraz oceny histopatologicznej, dokonanej przez
doświadczonego patologa. Niniejsza praca jest omówieniem tych zagadnień z perspektywy
lekarza patologa.
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Introduction
Extranodal lymphomas (EL), the neoplastic
lymphoproliferative lesions arising outside lymph
nodes, bone marrow, or spleen, can develop in ne-
arly every organ; however, the gastrointestinal
(GI) tract represents the most common site of EL
presentation [1]. While secondary involvement of
the GI tract by a nodal non-Hodgkin lymphoma
(NHL) is common, de novo extranodal GI lympho-
ma (EGIL) tracts are less common. These lesions
may affect any site along the GI tract and are tho-
ught to arise from primary/innate or acquired lym-
phoid elements distributed within the lamina pro-
pria and submucosa, including intra-epithelial lym-
phocytes.
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The difficulties in studying EGIL include the
relative rarity of these malignancies in relation to
their nodal counterparts, the wide range of clinical
presentations, varying locations within tissues, the
scarcity and often suboptimal preservation of the
diagnostic material, and difficulties in histopatho-
logic classification. Determination of a genuine de
novo EGIL is challenging since disseminated extra-
nodal cases and nodal cases with contiguous spre-
ad to the GI tract are much more common in clini-
cal practice. Moreover, frequencies and GI tract
distribution of EL differ among various countries
(Table 1) [1–7].
The gross appearance of EGIL within the GI
tract is variable and can range from polypoid lesions
to diffuse infiltration with or without ulceration or
necrosis, to exophytic masses, some of which may
endoscopically, radiologically, and grossly mimic the
appearance of a carcinoma. Too often, however, the
diagnoses of de novo EGIL is made on minute and
suboptimal biopsy material obtained endoscopical-
ly, highlighting the need for both clinicians and pa-
thologists alike to be ever vigilant for this entity.
De novo EGIL
Epidemiology and incidence
De novo EGIL represent 4–12% (depending on
the geographic location) of all NHL. As is the case
for nodal lymphomas, EGIL have been reported
with increasing frequency worldwide [8] with re-
sulting increase in morbidity and mortality [9]. This
trend is also noted in Canada, where the rates of
NHL in general have doubled since the 1970s, and
a similar trend is seen with de novo EGIL [9].
A recent study of an adult Canadian population be-
tween 1999 and 2003 demonstrated population-ba-
sed incidence rates of primary EGIL of 1.73 per
100,000, higher than in other parts of the western
world [7]. Similarly, a rising incidence of EGIL has
been documented in a comparable population be-
tween 1999 and 2009, with incidence for primary
colonic EGIL being nearly 5-fold greater than USA
rates documented in the 1990s [4, 10]. European
studies report the incidence varying between 0.58
and 1.25 per 100 000 (Table 1).
There is no clearly defined explanation for the
increases in EGIL occurrence, although it may be
explained in part by enhanced detection methods
increasing the awareness of this entity amongst
internists and gastroenterologists with common use
of endoscopy and colonoscopy in patients presen-
ting with vague abdominal symptoms, as well as
improved reporting and documentation of these le-
sions. Various reports indicate that the majority of
all EGIL are seen in the stomach (50–70%), less
commonly these are present in the small bowel
(25%) and least commonly in the colon (10–15%).
Only small case numbers have been reported wi-
thin the oesophagus [11, 12], vermiform appendix
[11, 13, 14], and anus. Approximately 10% of cases
will present with multiple sites of involvement
along the GI tract [15].
The majority of EGIL are diagnosed after age
55 (70–75%) and show slight male predominance
(M:F ratio of 1.5:1). This tendency is seen among
most of the NHL types with the exception of folli-
cular lymphoma (FL), which has a female prepon-
derance [15]. In the paediatric population, EGIL
most commonly occurs in the cecum [16–18] with
a proportion of cases localized to the vermiform
appendix [13]. The prognosis of these rare paedia-
tric cases appears to be excellent.
Predisposing factors
Several factors implicated in the development
of EGIL are well recognized and differ depending on
clinico-pathological entity. Gastric MALT (mucosa-
Table 1. Incidence of primary extranodal gastrointestinal lymphoma incidence rates from various studies
worldwide
Tabela 1. Częstość występowania pierwotnych pozawęzłowych chłoniaków przewodu pokarmowego
Country Study period Incidence (105) Reference
Denmark 1983–1991 1.19 [2]
Finland 1975–1993 1.25 [3]
United States 1978–1987 0.69 (whites) [4]
England & Wales 1986–1993 0.58 [5]
France 1976–1990 0.9 [6]
Canada 1999–2003 1.73 [7]
Canada 1999–2009 2.10 (in 2009) Howell et al. (manuscript submitted)
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-associated lymphoid tissue) lymphomas have been
attributed to chronic antigenic stimulation related to
infection with Helicobacter pylori (H. pylori), with re-
mission achieved following antibiotic treatment [19].
Immunoproliferative small intestinal disease
(IPSID), also known as an alpha chain disease, a rare
form of an extranodal marginal B cell lymphoma
(MZL), which arises in the small intestine (MALT)
causing diarrhoea and malabsorption, may respond
to antibiotic therapy and is believed to be related
to chronic infection with Campylobacter jejuni [20].
Celiac disease and certain serologic and genetic
factors (i.e. HLA-DQ2/DQ8) have been implicated
in the development of type I enteropathy-associa-
ted T-cell lymphoma (EATL). Immunocompromi-
se in the form of chronic human immunodeficiency
virus (HIV) infection, post-transplant immunosup-
pression, chemotherapy, or inflammatory bowel
disease have also been attributed to rises in EGIL
[21, 22]. Interestingly, HIV-associated EGIL shows
a continued decrease in incidence over time, a fin-
ding presumably related to restored immune sys-
tem defences with antiretroviral therapy [7]. The
latter supports the notion that the increased inci-
dence of EGIL is generally related to altered sys-
temic immunocompetence.
Clinical presentation
In general, patients with EGIL suffer less B-sym-
ptoms than their nodal counterparts. Clinical presen-
tation is dependent on the location of the extranodal
primary, and in the GI tract, symptoms depend on
lesion localization, i.e. stomach, small intestine, co-
lon, or rectum. The clinical presentations range from
discomfort, abdominal pain, and diarrhoea to surgi-
cal presentation of an abdominal mass, bowel ob-
struction, and acute abdomen with symptoms and
signs of perforation and/or haemorrhage.
Diagnostic imaging findings also vary depen-
ding on the lesion localization. Bone marrow invol-
vement is rare unless the extranodal disease has
become widely disseminated [1, 18, 23]. Other rare
endoscopic findings include case reports of a colo-
nic MALT lymphoma detected endoscopically as
a simple mucosal discoloration [24] or single or mul-
tiple polypoid lesions in mantle cell lymphoma
(MCL) and primary intestinal FL, respectively.
A case of atypical MALT in the transverse colon
with a secondary macroglobulinaemia has been re-
ported [25]. Presentations of EGIL mimicking der-
matomyositis or Crohn’s colitis are documented in
the literature [26–30]. Finally, EGIL has been as-
sociated with localized amyloidosis [31, 32].
Histological classification
Currently, the World Health Organization (WHO)
Classification of Tumours of Haematopoietic and
Lymphoid Tissue [15] set the diagnostic standard
for the morphological subclassification of NHL inclu-
ding EGIL. Within the GI tract, the various cate-
gories of de novo EGIL are subdivided into B- and
T/NK-cell neoplasms and post-transplant lympho-
proliferative disorders (PTLD) (Table 2).
This various morphologic subtypes of EGIL
also show differences in anatomic distribution. In
a recent study of a North American adult popula-
tion, a diffuse large B cell lymphoma (DLBCL) made
up the majority of lymphoma histologies along all are-
as of the GI tract including the stomach, small bo-
wel, colon, and various other multiple sites [10]. This
relative preponderance of DLBCL in de novo EGIL
is supported by other studies worldwide, in which
the histological subtype of EGIL was also a high
grade/DLBCL regardless of the GI site [5, 7]. Others
have shown a majority of de novo EGIL as being of
the extranodal MZL [2], or instances in which the
proportion of MZL/MALT and DLBCL classification
were approximately equal [33].
Staging
The consensus conference in Lugano in 1993
established staging of EGIL [34]. From this meeting
came specific criteria for determining the patholo-
gic staging of these lymphomas, with stage I tumo-
urs being confined to the GI tract, stage II demon-
strating local nodal involvement, and stage III in-
Table 2. World Health Organization (2008) histolo-
gical classification of extranodal gastrointestinal
non-Hodgkin’ lymphoma (source [15])
Tabela 2. Histologiczna klasyfikacja pozawęzłowych
chłoniaków nieziarniczych przewodu pokarmowego
według Światowej Organizacji Zdrowia (2008)
(źródło [15])
Mature B-cell neoplasms
Extranodal marginal zone lymphoma of mucosa-asso-
ciated lymphoid tissue (MALT lymphoma)
Follicular lymphoma including primary intestinal folli-
cular lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Burkitt lymphoma
Mature T-cell and NK-cell neoplasms
Enteropathy-associated T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Post-transplant lymphoproliferative disorders
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cluded with stage IV (bone marrow involved, any
extranodal involvement or GI tract lesion with su-
pra-diaphragmatic nodal involvement) (Table 3).
Prognostic factors
Various conflicting reports in the literature
exist as to prognostic factors in de novo EGIL, which
is probably related to morphologic heterogeneity.
Azab et al. [35] demonstrated by multivariate ana-
lysis that clinical stage, surgical resection, and hi-
stological grade all represent independent progno-
stic variables. For instance, in the stomach, MALT
lymphomas behave indolently, presenting as sta-
ge I or II disease, whereas transformation of this
lesion to a DLBCL, especially with bone marrow in-
volvement, results in a 5-year survival of 10% [36].
Molecular genetics in gastric MALT lympho-
mas also aid in predicting the biological behaviour
of these tumours and may help in guiding therapy.
For instance, t(11;18)-positive cases have inferior
response to H. pylori eradication therapy, but un-
dergo transformation to high grade histology at
much lower rates than their t(11;18)-negative co-
unterparts [37].
Diagnosis and ancillary studies
Diagnosis and further subclassification of the-
se neoplasms is based on comprehensive evaluation
of good quality morphology, immunophenotypic fe-
atures, and cytogenetic/molecular data, which to-
gether with clinical/endoscopic and radiological as-
sessment are usually helpful in subsequent sub-
classification. These studies, however, may not be
definitive in differentiating the neoplastic lesions
from reactive or oligoclonal/clonal atypical lympho-
cytic infiltrate.
Differentiating early extranodal MZL of MALT
type from exuberant chronic H. pylori gastritis with
associated lymphoid hyperplasia can be problema-
tic. The presence of oligoclonal/clonal B-cell expan-
sion in this context has to be interpreted with cau-
tion since clonally expanded B lymphocytes have
Table 3. Clinical staging of primary extranodal gastrointestinal non-Hodgkin lymphoma*
Tabela 3. Zaawansowanie kliniczne pierwotnie pozawęzłowych chłoniaków nieziarniczych przewodu pokar-
mowego*
Stage Tumour extenta
1993 Lugano Consensus Conference
I Tumour confined to GI tract:
• single primary site
• multiple non-contiguous lesions
II Tumour extending into abdomen from a GI primary:
II1 • local nodal involvement (para-gastric for gastric lymphomas; para-intestinal for intestinal
lymphomas)
II2 • distant nodal involvement (mesenteric in cases of intestinal primary; para-aortic,
para-caval, pelvic, inguinal)
IIE Penetration of serosa to involve adjacent organs/tissues
— e.g. IIE (site of adjacent organs/tissues)  Note: involvement of both nodal and
adjacent organs/tissues, designate as IIE1 or2
IVb Disseminated extranodal involvement or GI tract lesion with supra-diaphragmatic
nodal involvement
TNM classification of non-Hodgkin lymphomasa
IE Localized involvement of a single extralymphatic organ or site
IIE Localized involvement of single extralymphatic organ/site and regional lymph node(s) ±
± involvement of other lymph node regions on the same side of the diaphragm
IIIE Localized single extra-lymphatic organ/site and node regions on both sides of the diaphragm:
IIIS • or spleen
IIIE + S • or both
IV Disseminated (multifocal) involvement of one or more extralymphatic organs ± regional nodes
or extralymphatic organ involvement with distant (non-regional) nodal involvement
*Adapted from Rohatiner et al., 1994 and TNM Classification of Lymphomas (Sobin et al., 2010); aE indicates GI tract lesion extending to involve adjacent organs
(1993 Lugano Conference) but E denotes involvement of extralymphatic organs or sites in the TNM system; bstage III has been combined with Stage IV in the
1993 Lugano Consensus Conference; GI — gastrointestinal tract
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been reported in flow cytometric studies and poly-
merase chain reactions (PCR) in both EGIL and
biopsies harbouring chronic gastritis, as well as
colon biopsies showing non-specific colitis [38]. It
is generally accepted that clonal/oligo-clonal B-cell
expansions are not limited to neoplastic lymphopro-
liferative disorders but may also be seen in reactive
lesions. B-cell clonal bands are detected in cases of
H. pylori gastritis with associated lymphoid hyper-
plasia; however, the reproducibility of these bands
was limited and increased backgrounds were seen,
in contrast to low-grade MALT lymphomas [39].
MALT lymphomas may be associated with four
different types of mutations: the translocations
t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;21),
and t(3;14)(p13;q32). The genes affected by at le-
ast three of these mutations are involved in the
same pathway leading to the activation of the NFkB.
Of these, t(11;18) is the most specific and has
known clinical significance [40]. The MALT lym-
phoma with this particular translocation is unlikely
to respond to H. pylori eradication, which more com-
monly presents as a locally aggressive tumour
which usually does not transform into a high-grade
component [37].
Special topics in EGIL
MCL
Mantle cell lymphoma commonly presents with
stage III or IV with selected predilection for the GI
tract. Clinically the GI involvement may be silent,
but endoscopically widespread multiple lymphoma-
tous polypoid lesions are scattered throughout the
small and large intestine. A biopsy of these reveals
dense, monotonous lymphocytic infiltrate of centro-
cyte-like cells characteristically co-expressing CD20/
/BCL-2/CD5 and cyclin D1.
Other CD5-positive low-grade lymphomas
of the GI tract
Low-grade EGIL co-expressing CD5 and lac-
king cyclin D1 often presents considerable diagno-
stic difficulty, frequently magnified by the scarcity
of diagnostic material. Morphologically, these le-
sions may represent GI tract involvement by chro-
nic lymphocytic leukaemia (CLL)/small lymphocy-
tic lymphoma (SLL), to less commonly encounte-
red cyclin D1/D3 negative variant of MCL, extra-
nodal MZL resembling MALT type with atypical
CD5 expression or CD5 positive lymphoplasmacy-
tic lymphoma (LPL).
Primary intestinal FL
Nodal FL secondarily involving the GI tract is
well recognized. However, following a number of
case reports a distinct clinical presentation of de
novo FL exclusively limited to the GI tract with no
demonstrable clinical/radiological extension beyond
the GI tract has been described and adopted by
WHO classification as a novel clinico-pathological
entity [41, 42]. The single or multiple exophytic or
polypoid lesions usually affecting the upper GI tract
(duodenum) but also described in other GI parts
(colon) show morphologic and immunohistochemi-
cal features indistinguishable from the classic no-
dal counterpart. Immunophenotypically, these
CD20 positive lesions show distinct and bright co-
expression of BCL-2 protein and often demonstra-
te the presence of t(14;18). Whenever presenting
in limited stage (I/IIE) they invariably have an excel-
lent prognosis.
Burkitt lymphoma
Burkitt lymphoma (BL) is a highly aggressive
mature B-cell lymphoma with heterogenous pre-
sentation patterns. Four distinct epidemiological
variants are recognized: sporadic, endemic, HIV
infection related, and a type of PTLD. The latter two
subtypes may present as EGIL, are related to alte-
red immunocompetence of the host, and may be
lacking c-myc mutations. The sporadic variant,
which affects predominantly children and young
adults, usually presents as an extranodal tumour of
the ileocaecal region [43]. This subtype is variably
associated with the Epstein-Barr virus (EBV) (10–
–85% of cases), and most cases show the sole c-myc
mutation (90%).
The immunophenotype of BL is that of a ma-
ture B-cell neoplasm with tumour cells expressing
B-cell associated antigens (CD20, CD19, CD22,
CD79a), and germinal centre markers (CD10/BCL-6
and CD43). Progenitor markers (Tdt/CD34) are ty-
pically absent, and most of the cells are in prolife-
rative cycle as per high proliferative index Ki-67,
which commonly approaches 100%.
On occasion, BL may be difficult to differentiate
from DLBCL. Borderline cases, which present with
morphologic features of BL but lack the characte-
ristic high proliferative rate, immunohistochemical,
and/or cytogenetic signature, may currently be clas-
sified as B-cell lymphoma, unclassifiable, with fe-
atures intermediate between DLBCL and BL. This
distinction may not be important in a paediatric
population, where BL and DLBCL cases are treated
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in a similar fashion, but may alter the therapeutic
approach in an adult patient, where a more aggressi-
ve regimen with central nervous system prophylaxis
may be implemented in cases of BL/undetermined
B-cell category, as opposed to R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, predni-
sone) only commonly used in DLBCL patients.
PTLD
In the era of bone marrow and solid organ trans-
plantation, PTLD has emerged as a significant com-
plication of the necessary immunosuppression.
Most of these lesions are EBV-related and are of
B-cell origin. The gastrointestinal tract is one of the
most commonly affected systems. The incidence of
PTLD is dependent upon the type of transplanted
organ; small bowel transplants carry risk of 30%, he-
art, liver, lung, and pancreas 2–12%, while renal trans-
plants have the lowest risk at 1%. Several compre-
hensive reviews on this subject are available [44, 45].
T-cell lymphomas and celiac disease
Enteropathy-associated T-cell lymphoma (EATL)
is rare form of an extranodal T-cell lymphoma ari-
sing from intraepithelial T cells and affecting mo-
stly ileum and jejunum. Based on the morphology
and genetic profile, these have been divided into two
groups; type I EATL often has a background of re-
fractory celiac disease, malabsorption, and ulce-
rative jejunitis. Most cases, however, develop in
type II refractory celiac disease. These lymphomas
represent the majority of EATL (80%) and com-
monly affect patients of North European ancestry
[46]. Morphologically, they are composed of CD3-
and CD103-positive T-cells which are polymorpho-
us in size and shape, are often CD4/CD8/CD56-ne-
gative and may co-express CD30.
Much less common type II EATL, also known
as a monomorphic variant, is composed of small to
medium sized cytotoxic type CD8-positive T-cell
lymphocytes co-expressing CD56. This variant of
EATL often presents in the small bowel with symp-
toms of obstruction or perforation. It is not asso-
ciated with celiac disease and may represent a spo-
radic clinico-pathologic entity unrelated to risk
imposed by celiac disease [22]. All types of EATL
have an overall poor prognosis [15].
Extranodal NK/T-cell lymphoma
of the nasal type
This distinct and EBV-encoded RNA (EBER)-
-positive T cell lymphoma affecting the upper aero-
digestive tract also has an increased predilection for
skin and GI tract involvement. Clinically, it may
present as a surgical emergency with signs and
symptoms of acute abdomen and perforation. Sur-
gical procedure may procure resected sections of
bowel featuring necrotic and ulcerated lesions com-
posed of polymorphous infiltrate of CD56-positive
cytotoxic T/NK cells exhibiting a high degree of
EBER positivity, as demonstrated by in situ hybri-
dization. The CD30 expression present in some
subsets of these cases may result in misdiagnosis
with GI involvement by ALK-1 negative anaplastic
large cell lymphoma or EATL. Neither of these lat-
ter two T-cell lymphoma types, however, show such
a distinct EBER expression.
T-cell prolymphocytic leukaemia
T-cell prolymphocytic leukaemia (T-PLL),
known as T-cell CLL in the past, is a widely disse-
minated disease which may involve any portion of
the GI tract in a fashion similar to any low-grade
NHL. Morphologically, mature and variably convo-
luted lymphocytes permeate the tissue and charac-
teristically co-express CD2/CD3/CD5/CD7 mature
T-cell markers. In a considerable proportion of ca-
ses, co-expression of CD4/CD8 and TCL1 is diagno-
stic of this disease entity.
Benign NK-cell proliferations of the gut
Benign NK-cell enteropathy may present as
morphologically and immunophenotypically atypical
NK-cell lymphocytosis of the superficial mucosa in
a patient with endoscopic evidence of fold thickening,
superficial ulcerations which may be accompanied by
vague abdominal symptoms. An infiltrate of CD56/
/cCD3-positive NK-cells lacking surface expression
of CD3 is present. Commonly, both EBER and PCR
products indicating the presence of EBV DNA are
negative. This presentation usually results in exhau-
stive investigation and has yet to have a determined
significance, but its existence is important to avoid
pitfalls in calling these cases overtly malignant [47].
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